- Home
- ZYME vs CMPO Comparison
ZYME vs CMPO Comparison
Compare ZYME & CMPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- CMPO
- Stock Information
- Founded
- ZYME 2003
- CMPO 2000
- Country
- ZYME United States
- CMPO United States
- Employees
- ZYME N/A
- CMPO N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- CMPO Finance: Consumer Services
- Sector
- ZYME Health Care
- CMPO Finance
- Exchange
- ZYME Nasdaq
- CMPO Nasdaq
- Market Cap
- ZYME 983.6M
- CMPO 1.2B
- IPO Year
- ZYME 2017
- CMPO N/A
- Fundamental
- Price
- ZYME $11.91
- CMPO $10.87
- Analyst Decision
- ZYME Buy
- CMPO Strong Buy
- Analyst Count
- ZYME 6
- CMPO 8
- Target Price
- ZYME $19.50
- CMPO $16.19
- AVG Volume (30 Days)
- ZYME 728.6K
- CMPO 1.1M
- Earning Date
- ZYME 03-05-2025
- CMPO 03-05-2025
- Dividend Yield
- ZYME N/A
- CMPO 2.28%
- EPS Growth
- ZYME N/A
- CMPO N/A
- EPS
- ZYME N/A
- CMPO N/A
- Revenue
- ZYME $76,304,000.00
- CMPO $420,571,000.00
- Revenue This Year
- ZYME $19.85
- CMPO $8.91
- Revenue Next Year
- ZYME $100.06
- CMPO $8.74
- P/E Ratio
- ZYME N/A
- CMPO N/A
- Revenue Growth
- ZYME 0.38
- CMPO 7.67
- 52 Week Low
- ZYME $7.97
- CMPO $4.97
- 52 Week High
- ZYME $17.70
- CMPO $14.71
- Technical
- Relative Strength Index (RSI)
- ZYME 40.19
- CMPO 39.36
- Support Level
- ZYME $12.15
- CMPO $11.02
- Resistance Level
- ZYME $13.28
- CMPO $11.91
- Average True Range (ATR)
- ZYME 0.60
- CMPO 0.42
- MACD
- ZYME 0.03
- CMPO 0.04
- Stochastic Oscillator
- ZYME 22.22
- CMPO 33.76
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About CMPO CompoSecure Inc.
CompoSecure Inc is engaged in designing and manufacturing premium financial cards. The Company's metal payment card technology and Arculus security and authentication capabilities deliver premium branded experiences which enable people to access and use their assets, and ensure trust at the point of a transaction. Its products include Metal Cards and Arculus, a digital security platform. It has two reportable segments: Payment Card and Arculus.